Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia

Br J Haematol. 2018 Jan;180(2):301-304. doi: 10.1111/bjh.14322. Epub 2016 Sep 21.

Charles L Bennett^{1

2

3}, Joseph R Berger⁴, Oliver Sartor⁵, Kenneth R Carson⁶, William J Hrushesky^{1

2

3

7}, Peter Georgantopoulos^{1

2}, Dennis W Raisch⁸, LeAnn B Norris¹, James O Armitage⁹

¹ The Southern Network on Adverse Reactions (SONAR) Program, South Carolina College of Pharmacy, Columbia, SC, USA.
² The Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
³ SC Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
⁴ Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
⁵ Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA.
⁶ Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA.
⁷ Oncology Analytics Inc, Plantation, FL, USA.
⁸ College of Pharmacy, Pharmacoeconomics, Epidemiology, Public Policy, Outcomes Research Program, University of New Mexico, Albuquerque, NM, USA.
⁹ The University of Nebraska Medical Center, Omaha, NE, USA.

No abstract available

Keywords: chronic lymphyocytic leukaemia; ibrutinib; progressive multifocal leucoencephalopathy.

Publication types